Magnus Medical

Executive Summary

Magnus Medical is a San Francisco-based medical device company pioneering non-invasive neuromodulation for major depressive disorder (MDD). Its SAINT Depression Therapy is FDA-cleared and delivers rapid remission in a five-day accelerated protocol, addressing a critical unmet need for treatment-resistant depression. The therapy uses individualized fMRI-guided targeting and intermittent theta burst stimulation (iTBS) to achieve high remission rates with a favorable safety profile. As an early-stage private company, Magnus Medical is focused on commercializing SAINT Therapy through clinical adoption and reimbursement expansion. With a strong clinical evidence base and a growing market for treatment-resistant depression, the company is well-positioned for growth. However, commercial traction remains limited, and significant milestones such as payer coverage or additional FDA clearances are needed to drive valuation.

Upcoming Catalysts (preview)

• Q3 2026Publication of real-world outcomes or pivotal study results80% success
• Q4 2026FDA clearance for additional indication (e.g., anxiety disorders)40% success
• Q2 2026Commercial partnership or distribution agreement60% success